Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
DQ9HUBT8zsUrYkuF
